HARMONi-2 Shows Positive OS for Ivonescimab in First-Line PD-L1-Positive NSCLC

At the 2026 WCLC, the HARMONi-2 study presented updated overall survival data for ivonescimab versus pembrolizumab as first-line treatment for PD-L1-positive advanced NSCLC, showing a median OS of 30.8 months and a statistically significant, clinically meaningful positive OS result. Professor Chu Qian's interpretation noted consistent benefit across subgroups, with median OS exceeding three years in patients with high PD-L1 expression.